CL2011002782A1 - Combinacion farmaceutica antitumoral que comprende ave8062 y sorafenib, en forma de base o sal de acido util para tratar tumores solidos, como un sarcoma, cancer de pulmon, ovarios, riñon o higado. - Google Patents

Combinacion farmaceutica antitumoral que comprende ave8062 y sorafenib, en forma de base o sal de acido util para tratar tumores solidos, como un sarcoma, cancer de pulmon, ovarios, riñon o higado.

Info

Publication number
CL2011002782A1
CL2011002782A1 CL2011002782A CL2011002782A CL2011002782A1 CL 2011002782 A1 CL2011002782 A1 CL 2011002782A1 CL 2011002782 A CL2011002782 A CL 2011002782A CL 2011002782 A CL2011002782 A CL 2011002782A CL 2011002782 A1 CL2011002782 A1 CL 2011002782A1
Authority
CL
Chile
Prior art keywords
ave8062
sorafenib
sarcoma
ovarian
kidney
Prior art date
Application number
CL2011002782A
Other languages
English (en)
Inventor
Brigitte Vrignaud Patricia Demers
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CL2011002782A1 publication Critical patent/CL2011002782A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Combinación farmacéutica que comprende AVE8062 y sorafenib o sus sales; y su uso para la preparación de una combinación antitumoral.
CL2011002782A 2009-05-07 2011-11-04 Combinacion farmaceutica antitumoral que comprende ave8062 y sorafenib, en forma de base o sal de acido util para tratar tumores solidos, como un sarcoma, cancer de pulmon, ovarios, riñon o higado. CL2011002782A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0902210A FR2945210B1 (fr) 2009-05-07 2009-05-07 Combinaison antitumorale comprenant l'ave8062 et le sorafenib

Publications (1)

Publication Number Publication Date
CL2011002782A1 true CL2011002782A1 (es) 2012-03-30

Family

ID=41402172

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002782A CL2011002782A1 (es) 2009-05-07 2011-11-04 Combinacion farmaceutica antitumoral que comprende ave8062 y sorafenib, en forma de base o sal de acido util para tratar tumores solidos, como un sarcoma, cancer de pulmon, ovarios, riñon o higado.

Country Status (27)

Country Link
US (1) US20120108641A1 (es)
EP (1) EP2427185A1 (es)
JP (1) JP2012526090A (es)
KR (1) KR20120023754A (es)
CN (1) CN102438608A (es)
AR (1) AR076848A1 (es)
AU (1) AU2010244254A1 (es)
BR (1) BRPI1014197A2 (es)
CA (1) CA2761146A1 (es)
CL (1) CL2011002782A1 (es)
CO (1) CO6390102A2 (es)
CR (1) CR20110573A (es)
DO (1) DOP2011000335A (es)
EA (1) EA201171366A1 (es)
EC (1) ECSP11011440A (es)
FR (1) FR2945210B1 (es)
IL (1) IL216133A0 (es)
MA (1) MA33346B1 (es)
MX (1) MX2011011767A (es)
NI (1) NI201100191A (es)
PE (1) PE20120323A1 (es)
SG (1) SG175895A1 (es)
TN (1) TN2011000551A1 (es)
TW (1) TW201043225A (es)
UY (1) UY32618A (es)
WO (1) WO2010128259A1 (es)
ZA (1) ZA201108110B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012014732A (es) * 2010-06-18 2013-01-22 Sanofi Sa Una combinacion antitumoral que comprende ombrabulina un derivado de taxano y un derivado de platino.
EP2481404A1 (en) * 2010-11-15 2012-08-01 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
FR2968557A1 (fr) * 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
ES2627120T3 (es) 2011-07-08 2017-07-26 Helmholtz-Zentrum für Infektionsforschung GmbH Medicamento para el tratamiento del cáncer de hígado
FR2978662A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie
FR2978663A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie
WO2015126903A1 (en) * 2014-02-18 2015-08-27 Health Research, Inc. Combination therapy for hepatocellular carcinoma
KR102272993B1 (ko) * 2019-07-09 2021-07-06 충남대학교산학협력단 퀴니딘 유도체를 유효성분으로 함유하는 항암보조제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
ATE328599T1 (de) * 1998-04-03 2006-06-15 Ajinomoto Kk Antitumorale mittel
ES2377847T3 (es) 1999-01-13 2012-04-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
CN101816794A (zh) * 2001-06-25 2010-09-01 味之素株式会社 抗肿瘤剂
EP1474393A1 (en) * 2002-02-11 2004-11-10 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
WO2008031835A2 (en) * 2006-09-13 2008-03-20 Novartis Ag Method of treating autoimmune diseases using vegf-pathway inhibitors

Also Published As

Publication number Publication date
FR2945210A1 (fr) 2010-11-12
CO6390102A2 (es) 2012-02-29
TN2011000551A1 (fr) 2013-05-24
EA201171366A1 (ru) 2012-05-30
BRPI1014197A2 (pt) 2016-04-26
CN102438608A (zh) 2012-05-02
WO2010128259A1 (fr) 2010-11-11
UY32618A (es) 2010-12-31
NI201100191A (es) 2012-01-16
MA33346B1 (fr) 2012-06-01
CR20110573A (es) 2011-12-08
CA2761146A1 (fr) 2010-11-11
TW201043225A (en) 2010-12-16
FR2945210B1 (fr) 2011-07-01
DOP2011000335A (es) 2011-12-15
MX2011011767A (es) 2012-02-28
US20120108641A1 (en) 2012-05-03
ZA201108110B (en) 2013-01-30
AU2010244254A1 (en) 2011-11-24
KR20120023754A (ko) 2012-03-13
SG175895A1 (en) 2011-12-29
PE20120323A1 (es) 2012-04-17
IL216133A0 (en) 2012-01-31
AR076848A1 (es) 2011-07-13
ECSP11011440A (es) 2011-12-30
JP2012526090A (ja) 2012-10-25
EP2427185A1 (fr) 2012-03-14

Similar Documents

Publication Publication Date Title
CL2011002782A1 (es) Combinacion farmaceutica antitumoral que comprende ave8062 y sorafenib, en forma de base o sal de acido util para tratar tumores solidos, como un sarcoma, cancer de pulmon, ovarios, riñon o higado.
CY1119960T1 (el) Μεθοδοι για την αυξηση της αποτελεσματικοτητας της folr1 θεραπειας του καρκινου
CL2016001616A1 (es) Moduladores de dll3 y sus métodos de uso (divisional de sol. n° 2240-14).
ECSP14012726A (es) Compuestos terapéuticamente activos y sus métodos de uso
BR112013028422A2 (pt) ativadores de piruvato cinase para uso em terapia
CL2016000373A1 (es) Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
ECSP14033037A (es) Síntesis de compuestos heterocíclicos
CL2011002943A1 (es) Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica.
SV2016005149A (es) Polimorfo de los inhibidores de la syk
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
CO6900118A2 (es) Métodos para tratar el cancer por el uso de antagonistas de unión al eje pd-1e inhibidores de mek
UY34453A (es) Moléculas de unión para bcma y cd3
CL2015000094A1 (es) Compuestos derivados de imidazotriazincarbonitrilos, inhibidores de la proteina cinasa; composicion farmaceutica que los comprende; y su uso para tratar el cancer, psoriasis y artritis reumatoide.
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
CO7151485A2 (es) Anticuerpos anti-sez6 y métodos de empleo
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
EA201400178A1 (ru) Лечение рака молочной железы
BR112013029787A2 (pt) biomarcadores para câncer de pulmão
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
BR112013029773A2 (pt) canabinoides para uso no tratamento de dor neuropática
CL2008001323A1 (es) Compuestos derivados de triazolil aminopiridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.